Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,027 total articles
Safe Pro Group Inc. announced record second quarter 2026 financial results with revenues surging 1,336% year-over-year to $1.33 million driven by multiple U.S. government contracts for their AI-powered NODE and SPOTD threat detection and mapping solutions. The company's AI gross margin reached 75%, highlighting high scalability and profitability. K…
Evaxion A/S, a clinical-stage TechBio company utilizing its AI-Immunology platform for vaccine development, announces it will release its second quarter 2026 financial results and provide a business update on August 20, 2026. The company will host a conference call and webcast presenting these details to investors and analysts.
Allarity Therapeutics reported Q2 2026 financial results showing a solid cash position of $26.9 million and operational progress including a key U.S. patent granting long-term exclusivity for its stenoparib-specific companion diagnostic to 2042. The company completed its Phase 3-ready stenoparib API manufacturing campaign ahead of schedule, obtaine…
Dycom Industries, Inc., a provider of specialty contracting services to telecommunications and utility sectors, will hold its fiscal 2027 second quarter results call on August 26, 2026. The company plans to release its financial results earlier that day, with a conference call and webcast to follow for investors and interested parties.
PMV Pharmaceuticals reported second quarter 2026 financial results highlighting completion of enrollment for the Phase 2 monotherapy portion of the PYNNACLE clinical trial for rezatapopt targeting platinum-resistant/refractory ovarian cancer patients. The company plans to submit a New Drug Application (NDA) in Q1 2027. Cash position stands at $79.4…
GT Biopharma announced its second quarter 2026 financial results, reporting ongoing Phase 1 clinical trials for two TriKE candidates targeting hematologic malignancies and solid tumors, respectively. The company has $5.1 million in cash expected to fund operations through Q4 2026, with R&D and SG&A expenses rising due to trial activity and marketin…
IES Holdings, Inc. announced that its President & CEO and CFO will present at the Midwest IDEAS Investor Conference on August 27, 2026, in Chicago. The presentation will be webcast and materials will be available on their investor relations website. IES is a US-based company specializing in electrical and technology systems installation and infrast…
Galectin Therapeutics reported Q2 2026 financial results and provided updates on its lead drug belapectin targeting MASH cirrhosis and portal hypertension. The company reached agreement with the FDA on key design elements of the planned registrational Phase 3 trial, validating its regulatory pathway. New clinical data reinforcing belapectin's poten…
Foremost Clean Energy Ltd. announced the grant of 68,000 stock options to certain officers, employees, and consultants under its Long-Term Incentive Plan. The options have an exercise price of $1.87, vest over three years, and have a five-year term. The company focuses on uranium, lithium, and gold exploration in North America, supporting carbon-fr…
Annovis Bio reports successful full enrollment of its pivotal Phase 3 clinical trial for buntanetap in early Alzheimer's disease, surpassing target patient numbers. The company also progresses its Parkinson's disease open-label extension study and prepares for initial data readout in early 2027, supporting upcoming regulatory steps. Financially, An…
Replimune Group, Inc. announced FDA accelerated approval of TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for treating unresectable advanced cutaneous melanoma patients who progressed after PD-1 antibody treatment. The company is preparing to launch the product in the U.S. within 60 days. They strengthened their commercial…
CSP Inc., a US-based security and technology solutions company, announced its third quarter fiscal 2026 financial results, showing stable sales with a slight decline due to hardware supply delays but improved gross margins and a 100% customer renewal rate for its AZT PROTECT product. The company secured significant new contracts including a large m…
Lantheus Holdings announced FDA approval of TAUKLARIFY™ (florquinitau F 18 injection), a radiodiagnostic PET imaging agent that identifies tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. Supported by clinical trials demonstrating high accuracy and safety, TAUKLARIFY complements exist…
Quince Therapeutics completed its acquisition of Orphai Therapeutics, adding the inhaled rapamycin formulation LAM-001 to its pipeline targeting serious pulmonary diseases. The company initiated a Phase 2b trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and expects key data from ongoing trials in bronchiolitis obl…
SurgePays, Inc. disclosed strong financial results for Q2 2026, with revenue growing 40.7% year-over-year to $16.2 million, marking the sixth consecutive quarter of sequential revenue growth. The company also achieved a positive net income of $1.29 million, returning to GAAP profitability. First half 2026 revenue rose 45.7% compared to the prior ye…
LanzaTech Global, Inc. announced its Q2 2026 financial results showing a slight decline in revenue but substantial improvement in operating expenses and net income driven by cost optimization and unrealized gains from its SGLT investment. The company advanced its position towards pioneering the world's first ISCC EU certification for recycled carbo…
Milestone Scientific Inc. reported a 22% year-over-year revenue increase for Q2 2026 to $2.8 million, driven by a 231% surge in medical segment sales, particularly CompuFlo®. The company reaffirmed a 2026 outlook of double-digit revenue growth, highlighting strategic distribution agreements expanding access to federal healthcare systems and Medicar…
Edible Garden AG Incorporated reported a 12.8% increase in revenue to $3.6 million and a 31.2% increase in total sales for Q2 2026, driven by strong growth in fresh-cut herbs, condiments, and international vitamins. The company expanded retail partnerships, including new distribution agreements with Target, Kroger, and Weis Markets, and progressed …
Diginex Limited announced an extraordinary general meeting scheduled for October 8, 2026, seeking shareholder approval for its proposed acquisition of Resulticks Global Companies. The acquisition consideration involves issuing 600 million new shares of Diginex at $1.75 per share. Additionally, Diginex plans to increase authorized share capital and …
Beneficient, a Nasdaq-listed technology-enabled platform for alternative asset liquidity and capital solutions, reported its Q1 FY 2027 results showing progress in strategic initiatives. Key developments include securing its first collateral management services agreement with a Texas state-chartered bank, generating expected recurring fee revenue, …
Super League Enterprise, Inc. announced second quarter 2026 financial results showing sequential net revenue growth of 16%, gross margin expansion to 41%, and a 20% year-over-year improvement in adjusted EBITDA, despite flat gross revenue in a tough advertising environment. The company successfully integrated Misfits Ads assets without raising cost…
Wrap Technologies has been chosen by WOFT Charities to provide training services for a newly funded $475,000 Teacher Safety Training Program in Florida. This program aims to enhance situational awareness and safety skills among teachers and school personnel, expanding Wrap’s public safety training expertise beyond law enforcement into education.
BridgeBio Pharma announced the pricing of a secondary offering of 5 million shares of common stock by selling shareholder KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive proceeds from this transaction. The offering aims to diversify and evolve BridgeBio's institutional shareholder base toward long-term, high-…
Helus Pharma reported Q1 Fiscal 2027 results highlighting completion of enrollment in its Phase 3 APPROACH study for HLP003 in Major Depressive Disorder with top-line data expected in Q4 2026. The company appointed Michael Halstead as CEO to lead late-stage development and commercialization efforts. Its Phase 2 candidate HLP004 showed meaningful im…
Outlook Therapeutics announced its Q3 fiscal 2026 financial results and detailed progress toward the U.S. commercial launch of LYTENAVA™, the only FDA-approved ophthalmic bevacizumab for wet age-related macular degeneration (wet AMD). The company aims to launch LYTENAVA in the U.S. by the end of 2026 and projects potential annual sales exceeding $5…
